Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.
about
New Strategies for the Treatment of Solid Tumors with CAR-T CellsRole of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer TreatmentEmerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cellsNatural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain.Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis.Immunooncology: Can the Right Chimeric Antigen Receptors T-Cell Design Be Made to Cure All Types of Cancers and Will It Be Covered?Tracking dendritic cell migration into lymph nodes by using a novel PET probe 18F-tetrafluoroborate for sodium/iodide symporter.RGIFE: a ranked guided iterative feature elimination heuristic for the identification of biomarkers.Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade.Immune Therapy for Prostate Cancer.Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer.Two is better than one: advances in pathogen-boosted immunotherapy and adoptive T-cell therapy.The molecular biology of prostate cancer: current understanding and clinical implications.The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
P2860
Q26748500-3A3276CC-6CD4-48BD-96D7-D90E5AB39166Q33718182-297EBCEF-5D84-4BD0-AC3A-45CACDCFE981Q33833475-0F1E22E0-57B7-4F46-A38F-793FFA7634CEQ35878535-BA7C06FF-0FA4-4458-A5BA-31D0BAE1F02CQ36201736-C31F07E7-B969-438F-A384-BF6AEE03FDBEQ37625303-4CB8E99C-C4E3-48B9-AFD5-3B475EE13BB1Q37737503-DA564FF2-71F1-4BB4-B2D6-11F1622D17E3Q38699741-6573E4B6-EC7D-46C6-B50C-A4F646564CF2Q38787449-62CA96ED-6822-4DC7-896C-5AB7CE2769CEQ38874911-EECBCD21-B95B-40DF-B799-82F4D16F13F2Q38982667-16F975F7-277F-49F0-9E99-6F435416CCBCQ41660817-1C3DF950-8115-412E-894B-F83AEDC6236FQ47129409-23475C35-5C61-466A-80CA-C5FFCCC269EFQ47709474-6DB4A7D3-0582-49C9-9255-05558D2C21C7Q49546811-05AC5A11-DE32-41DB-891F-EA60BF362E6AQ57177485-D0668C52-2D8E-4B71-BAB7-4B9149743FEF
P2860
Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Chimeric antigen receptor-engi ...... of metastatic prostate cancer.
@ast
Chimeric antigen receptor-engi ...... of metastatic prostate cancer.
@en
type
label
Chimeric antigen receptor-engi ...... of metastatic prostate cancer.
@ast
Chimeric antigen receptor-engi ...... of metastatic prostate cancer.
@en
prefLabel
Chimeric antigen receptor-engi ...... of metastatic prostate cancer.
@ast
Chimeric antigen receptor-engi ...... of metastatic prostate cancer.
@en
P2860
P921
P1433
P1476
Chimeric antigen receptor-engi ...... of metastatic prostate cancer.
@en
P2093
Magnus Essand
Victoria Hillerdal
P2860
P2888
P356
10.1007/S40259-015-0122-9
P5008
P577
2015-04-01T00:00:00Z